Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
90-Y-ibritumomab tiuxetan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8 | EXPERIMENTAL | For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label). |
| Name | Type | Description |
|---|---|---|
| 90-Y-ibritumomab tiuxetan | BIOLOGICAL | IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period. |
| rituximab | BIOLOGICAL | Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose. |
| indium In 111 ibritumomab tiuxetan | RADIATION | IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body. |
DISEASE CHARACTERISTICS: Histologically proven relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL) Prior rituximab allowed if no response achieved CD20-positive B-cells in lymph nodes or bone marrow required for small lymphocytic or transformed NHL Less ...
Top 20 of 66 competitors
90-Y-ibritumomab tiuxetan is used for the treatment of lymphoma, including non-Hodgkin's lymphoma. It is a monoclonal antibody being developed by Biogen Inc. for oncology indications. The drug is currently in clinical development and has been studied in patients with relapsed or refractory non-Hodgkin's lymphoma.
90-Y-ibritumomab tiuxetan is a monoclonal antibody that targets CD20, a protein found on the surface of B-cells. By binding to CD20, the drug delivers a radioactive isotope, yttrium-90, directly to cancer cells, which helps to destroy them. This targeted approach is designed to treat lymphoma while minimizing damage to healthy cells.
90-Y-ibritumomab tiuxetan is developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is responsible for the clinical development and manufacturing of this investigational monoclonal antibody for the treatment of lymphoma.
90-Y-ibritumomab tiuxetan is in Phase 2 clinical development. It has completed one Phase 2 trial and one Phase 1 trial. The drug is investigational and has not been approved by the FDA. It is still being studied to evaluate its safety and efficacy in patients with lymphoma.
90-Y-ibritumomab tiuxetan has been studied in two completed clinical trials. NCT00005592 was a Phase 2 trial in patients with relapsed or refractory non-Hodgkin's lymphoma. NCT00186589 was a Phase 1 trial combining the drug with high-dose chemotherapy and autologous transplantation for relapsed or resistant non-Hodgkin's lymphoma.
90-Y-ibritumomab tiuxetan is a radiolabeled form of ibritumomab tiuxetan, where the antibody is conjugated to the radioactive isotope yttrium-90. This form is specifically designed for radioimmunotherapy, delivering radiation directly to cancer cells. It is being studied for the treatment of lymphoma.